# Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma

> **NCT05109052** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **University of Rochester**

## Conditions studied

- Hepatocellular Carcinoma
- Cancer of Liver

## Interventions

- **DRUG:** PXS-5505 and Atezolizumab and Bevacizumab

## Key facts

- **NCT ID:** NCT05109052
- **Lead sponsor:** University of Rochester
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-09-20
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** no accrual of eligible participants
- **Last updated:** 2023-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05109052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05109052, "Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05109052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*